Study of AZD5305 as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Malignancies
ID: NCT04644068
Our intelligence engine has synthesized this trial record to answer your most important questions in clear, simple terms:
This research is designed to determine if experimental treatment with PARP inhibitor, AZD5305, alone, or in combination with anti-cancer agents is safe, tolerable, and has anti-cancer activity in patients with advanced solid tumors.
Read Full Scientific Objectives & Methods
This study is a Phase I/IIa modular, open-label, multi-center study of AZD5305 administered orally, either as monotherapy or in combination with other anti-cancer agents in patients with advanced solid malignancies.
Oral PARP inhibitor
IV Anti-microtubule agent
IV Platinum chemotherapeutic
IV Antibody-drug conjugate
IV Antibody-drug conjugate
Oral SERD Molecule
Treatment Arms Description
AZD5305 Monotherapy
AZD5305 + Paclitaxel
AZD5305 + Carboplatin with or without Paclitaxel
AZD5305 + T- DXd
AZD5305 + Dato-DXd
AZD5305 + Camizestrant
- Age ≥ 18 at the time of screening
- Histological or cytological confirmation of advanced malignancy considered to be suitable for study treatment and meeting module specific eligibility criteria..
- Eastern Cooperative Oncology Group Performance status (ECOG PS: 0-2)
- Life expectancy ≥ 12 weeks
- Progressive cancer at the time of study entry
- Patients must have evaluable disease as defined in module-specific criteria for Part A and Part B
- Adequate organ and marrow function as defined by the protocol.
- For Part B expansion cohorts: Provision of formalin-fixed and paraffin embedded (FFPE) tumour specimen is mandatory, where available, except if stated that it is optional in a specific Module.
- For Part A:
- \- Patients may have received up to one prior line of therapy with a PARPi-based regimen (either as a treatment or as maintenance)
- For Part B:
- \- Patients must not have received prior therapy with a PARPi-based regimen (either as a treatment or as maintenance).
- Treatment with any of the following:
- Nitrosourea or mitomycin C within 6 weeks of the first dose of study treatment
- Any investigational agents or study drugs from a previous clinical study within 5 half-lives or 3 weeks (whichever is shorter) of the first dose of study treatment
- Any other chemotherapy, immunotherapy or anticancer agents within 3 weeks of the first dose of study treatment
- Any live virus or bacterial vaccine within 28 days of the first dose of study treatment
- Concomitant use of medications or herbal supplements known to be cytochrome P450 3A4 (CYP3A4) strong inhibitors or inducers.
- Concomitant use of drugs that are known to prolong or shorten QT and have a known risk of Torsades de Pointes.
- Receiving continuous corticosteroids at a dose of \>10 mg prednisone/day or equivalent for any reason.
- Major surgery within 4 weeks of the first dose of study treatment.
- Radiotherapy with a wide field of radiation within 4 weeks or radiotherapy with a limited field of radiation for palliation within 2 weeks of the first dose of study treatment.
- Any history of persisting (\> 2 weeks) severe pancytopenia due to any cause
- Spinal cord compression or brain metastases unless asymptomatic, treated and stable and not requiring continuous corticosteroids at a dose of \>10mg prednisone/day or equivalent for at least 4 weeks prior to start of study treatment. Patients with leptomeningeal carcinomatosis are excluded.
- patient with known predisposition to bleeding (e.g., active peptic ulceration, recent \[within 6 months\] haemorrhagic stroke, proliferative diabetic retinopathy).
- Cardiac conditions as defined by the clinical study protocol
- Other cardiovascular diseases as defined by any of the following:
- Symptomatic heart failure,
- uncontrolled hypertension,
- hypertensive heart disease with significant left ventricular hypertrophy
- acute coronary syndrome (ACS)/acute myocardial infarction (AMI), unstable angina pectoris, coronary intervention procedure with percutaneous coronary intervention (PCI) or coronary artery bypass grafting (CABG) within 6 months.
- cardiomyopathy of any etiology
- presence of clinically significant valvular heart disease
- history of atrial or ventricular arrhythmia requiring treatment; subjects with atrial fibrillation and optimally controlled ventricular rate (\< 100 beats per minute) are permitted.
- subjects with atrial fibrillation and optimally controlled ventricular rate are permitted
- transient ischaemic attack, or stroke within 6 months prior to screening
- patients with symptomatic hypotension at screening
- Patients with myelodysplastic syndrome/acute myeloid leukaemia or with features suggestive of myelodysplastic syndrome (MDS)/acute myeloid leukaemia (AML).
- Refractory nausea and vomiting, chronic gastrointestinal diseases, inability to swallow the formulated product or previous significant bowel resection that would preclude adequate absorption of AZD5305
- Known allergy or hypersensitivity to investigational product(s) or any of the excipients of the investigational product(s).
- Prior malignancy whose natural history, in the Investigator's opinion, has the potential to interfere with safety and efficacy assessments of the investigational regimen.
- other module-specific criteria may apply
Primary Outcome Measures
- The number of subjects with adverse events/serious adverse events — Time Frame: From time of Informed Consent to 28 + 7 days post last dose ( modules 1,2,3,5 and 6). 40+7 days post last dose for Module 4.
Number of patients with adverse events and with serious adverse events including abnormal clinical observations, abnormal ECG parameters, abnormal laboratory assessments and abnormal vital signs that changed from baseline
- The number of subjects with dose-limiting toxicity (DLT), as defined in the protocol. — Time Frame: From first dose of study treatment until the end of Cycle 1.
A DLT is defined as any toxicity that occurs from the first dose of study treatment (either AZD5305 or combination anti-cancer agent) up to and including the planned end of Cycle 1 (the DLT assessment period) that is assessed as unrelated to the disease or disease-related processes under investigation. DLTs occurring outside the DLT window (ie, late onset toxicities) may be defined as a DLT after consultation with the sponsor and investigators, based on the emerging safety profile.
View Secondary Outcome Measures (33)
- Best percentage change in target lesion — Time Frame: From Screening to confirmed progressive disease (approximately 1 year)
Change in target lesion size from baseline, as defined by RECIST 1.1.
- Objective Response Rate — Time Frame: From Screening to confirmed progressive disease (approximately 1 year)
Best response until progression, as defined by RECIST 1.1.
- Duration of Response — Time Frame: From Screening to confirmed progressive disease (approximately 1 year)
Time from first response to progression or death , as defined by RECIST 1.1.
- Progression Free Survival — Time Frame: From Screening to confirmed progressive disease (approximately 1 year)
Time from C1D1 to progression or death, as defined by RECIST 1.1.
- Time To Response — Time Frame: From Screening to confirmed progressive disease (approximately 1 year)
Time from C1D1 to complete or partial response, as defined by RECIST 1.1.
- Effects of AZD5305 on pH2AX (Ser139) PD biomarker — Time Frame: From Cycle 0 Day 1 to Cycle 1 Day 15 (approximately 21 days)
Measure change from baseline in pH2AX
- CA125 response (ovarian cancer) — Time Frame: From Screening to confirmed progressive disease (approximately 1 year)
at least a 50% reduction in CA125 levels from a pre-treatment sample as defined by GCIG criteria.
- Module 1: Area Under Curve (AUC) — Time Frame: At predefined intervals throughout the treatment period (approximately 12 weeks)
The concentration of AZD5305 in plasma will be determined. Area under the curve is the integral of the concentration-time curve. The AUC reflects the actual body exposure to drug after administration. The AUC is dependent on the rate of elimination of the drug from the body and the dose administered.
- Module 1: Maximum plasma concentration of the drug (Cmax) — Time Frame: At predefined intervals throughout the treatment period (approximately 12 weeks)
The concentration of AZD5305 in plasma will be determined (Cmax will be derived).
- Module 1: The time taken to reach the maximum concentration (Tmax) — Time Frame: At predefined intervals throughout the treatment period (approximately 12 weeks)
The concentration of AZD5305 in plasma will be determined (Tmax will be derived).
This trial is recruiting at 68 study facilities worldwide. Click below to see if there is a clinic or hospital in your area:
Show All 68 Facilities & Contact Sites
Want to apply or inquire about joining this study? Fill out this simple questionnaire, and our assistant will instantly generate a professional email draft you can copy and send to the central contact coordinator listed above!
- Illuzzi G, Staniszewska AD, Gill SJ, Pike A, McWilliams L, Critchlow SE, Cronin A, Fawell S, Hawthorne G, Jamal K, Johannes J, Leonard E, Macdonald R, Maglennon G, Nikkila J, O'Connor MJ, Smith A, Southgate H, Wilson J, Yates J, Cosulich S, Leo E. Preclinical Characterization of AZD5305, A Next-Generation, Highly Selective PARP1 Inhibitor and Trapper. Clin Cancer Res. 2022 Nov 1;28(21):4724-4736. doi: 10.1158/1078-0432.CCR-22-0301.PubMed ↗
View Official Medical/Scientific Title
A Modular Phase I/IIa, Open-label, Multicentre Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of Ascending Doses of AZD5305 as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Malignancies